Genmab — Februar 2020

[GeorgeBest]

Forøvrigt købte Jan en ordentlig bunke aktier da han lige var blevet CEO. Da tog han en enorm risiko, hvor selskabet blødte og i den grad var truet på livet...

[bikube]

Og Jan har købt en del af sine aktier i det fri marked, som vi andre har. Det er ikke kun hans warrants.

[GeorgeBest]

Solsen, jo der er en til at man satser kassen på 1BB på dette meget tidlige tidspunkt. THE NEXT WINNER

[GeorgeBest]

grund til

[GeorgeBest]

GEN1046

[Solsen]

DuoBody-PD-L1x4-1BB, one of the products that we are developing along with BioNTech, has the potential to be first-in-class and to provide Genmab with a truly differentiated PD-L1 products. There is a high unmet medical need to improve on checkpoint blockers, and we have seen strong pre-clinical data and encouraging early signs of activity in patients who failed PD-1 and/or PD-L1 checkpoint blockers for DuoBody-PD-L1x4-1BB.

[Solsen]

Fra transcript..

[Helge_LarsenPI-redaktør]

God morgen.

[transalp]

Go morgen..

[bibob]

God aften.

[transalp]

[StockBull]

Morn Så er corona panikken kommet til Europa - DAX -1.75%, NAS -1.6.

[StockBull]

Børsen Korona: https://borsen.dk/nyheder/morgenbriefing/artikel/1/396546/morgenbriefing_coronavirus_spreder_sig_store_aktiefald_verden_over.html?utm_source=forside&utm_campaign=nyhed_01

[StockBull]

Live Corona update: https://www.worldometers.info/coronavirus/

[Helge_LarsenPI-redaktør]

God morgen.

[JKY_VH]

God morgen;-)

[bibob]

God morgen.

[GeorgeBest]

U.S. FDA Filing Acceptance and Priority Review for sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis

[GeorgeBest]

Novartis anticipates potential regulatory approval in the U.S. in June 2020

[GeorgeBest]

Marketing Authorization Application for ofatumumab in RMS also accepted for review by EMA with potential regulatory approval anticipated by Novartis by the second quarter of 2021